The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.65
Bid: 0.60
Ask: 0.70
Change: -0.10 (-13.33%)
Spread: 0.10 (16.667%)
Open: 0.75
High: 0.75
Low: 0.65
Prev. Close: 0.75
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re Investment

4 Apr 2016 08:57

RNS Number : 0259U
Onzima Ventures PLC
04 April 2016
 

Onzima Ventures PLC

("Onzima" or the "Company")

Investee company N4 Pharma announces messenger RNA vaccine program

Onzima is pleased to announce that N4 Pharma Limited ("N4 Pharma") its 49%-owned investee company, has extended its relationship with the University of Queensland ("Uniquest") to include the exclusive global rights to commercialise their nano particle vaccine delivery system for messenger RNA (mRNA) particles. This adds to the rights it already has for plasmid DNA and certain subunit vaccines.

Under this agreement N4 Pharma will undertake further research and experimentation with Uniquest to develop a strong in-vitro data package demonstrating the ability of these vectors to achieve high protective loading of pDNA and mRNA and demonstrate their strong transfection capability.

N4 Pharma CEO Nigel Theobald commented:

"mRNA is an exciting area of therapeutic treatment in oncology and early encouraging results with our plasmid DNA research show strong pDNA loading onto the silica vesicle and excellent transfection being achieved.

Over the next few months we will continue to undertake experiments to demonstrate the capability of our vectors for both pDNA and mRNA, publishing the data when we can with a view to looking to engage with potential partners in the second half of 2016 to either work with their own particles or potentially acquire the rights to particles ourselves which we can then seek to take forward using these vectors.

The recent investment by Onzima Ventures has allowed us to develop our intellectual property portfolio and create two extremely strong drug delivery/reformulation platforms, one for small molecules and another for vaccines and oncology treatments. Our aim now is to develop strong commercial propositions using our IP and seek partnerships and funds to take forward specific projects."

For further information please contact:

Onzima Ventures PLC Tel: +44 (0) 1622 717700

Gavin Burnell, Luke Cairns

 

Nominated Adviser

Cairn Financial Advisers LLP Tel: +44 (0) 20 7148 7900

Sandy Jamieson, Liam Murray

 

Broker

Peterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930

Guy Miller, Lucy Williams

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXLLESLKEEF
Date   Source Headline
25th Feb 20207:00 amRNSFinal Results
11th Feb 20207:00 amRNSResearch Collaboration Agreement
29th Jan 20207:00 amRNSUpdate on Nuvec® process improvements
18th Sep 20197:00 amRNSInterim Results
20th Aug 20197:00 amRNSResults of University of Queensland Study
13th Aug 201911:16 amRNSHolding(s) in Company
15th Jul 20192:05 pmRNSSecond Price Monitoring Extn
15th Jul 20192:00 pmRNSPrice Monitoring Extension
3rd Jul 20194:40 pmRNSSecond Price Monitoring Extn
3rd Jul 20194:35 pmRNSPrice Monitoring Extension
19th Jun 201912:51 pmRNSResult of AGM
19th Jun 20197:00 amRNSAGM Statement
14th Jun 20194:41 pmRNSSecond Price Monitoring Extn
14th Jun 20194:36 pmRNSPrice Monitoring Extension
28th May 20192:21 pmRNSChange to Director Shareholding
22nd May 20197:00 amRNSPosting of Annual Report and Notice of AGM
21st May 20197:00 amRNSBoard Changes
14th May 20197:00 amRNSFinal Results
15th Apr 20197:00 amRNSNuvec® Research update
10th Apr 201911:52 amRNSDirector/PDMR Shareholding
9th Apr 20197:00 amRNSNuvec® Research update
20th Mar 20199:40 amRNSHolding(s) in Company
20th Mar 20199:40 amRNSHolding(s) in Company
28th Feb 20195:00 pmRNSTotal Voting Rights
14th Feb 20192:14 pmRNSHolding(s) in Company
8th Feb 201912:23 pmRNSPlacing to raise £1.05 million
20th Dec 20187:00 amRNSNuvec licence extension
28th Nov 20187:00 amRNSNuvec® research update
16th Nov 20181:36 pmRNSNuvec resource changes
15th Nov 20187:00 amRNSFiling of further Nuvec® patent application
14th Nov 201811:05 amRNSSecond Price Monitoring Extn
14th Nov 201811:00 amRNSPrice Monitoring Extension
14th Nov 20189:05 amRNSSecond Price Monitoring Extn
14th Nov 20189:00 amRNSPrice Monitoring Extension
8th Nov 20184:40 pmRNSSecond Price Monitoring Extn
8th Nov 20184:35 pmRNSPrice Monitoring Extension
8th Nov 20182:05 pmRNSSecond Price Monitoring Extn
8th Nov 20182:00 pmRNSPrice Monitoring Extension
5th Nov 201811:06 amRNSSecond Price Monitoring Extn
5th Nov 201811:00 amRNSPrice Monitoring Extension
5th Nov 20189:00 amRNSPrice Monitoring Extension
5th Nov 20187:54 amRNSResearch collaboration update
29th Oct 20187:00 amRNSNuvec® research update
2nd Oct 201811:44 amRNSResearch collaboration for novel DNA vaccine
26th Sep 20181:48 pmRNSGrant of options
26th Sep 201811:00 amRNSPrice Monitoring Extension
24th Sep 20184:41 pmRNSSecond Price Monitoring Extn
24th Sep 20184:35 pmRNSPrice Monitoring Extension
24th Sep 20182:05 pmRNSSecond Price Monitoring Extn
24th Sep 20182:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.